|
|
|
|
Central Nervous System Disorders Therapy: Investigators at Boehringer Ingelheim GmbH release new data on central nervous system disorders therapy
Central Nervous System Disorders Therapy New research, 'The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease,' is the subject of a report.According to recent research from Biberach, Germany...
|
|
|
Roche uniquely positioned to deliver long-term growth
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.At its first investor conference following the...
|
|
|
EMA Grants to ADIENNE Exclusive Marketing Authorization for TEPADINA
European Medicines Agency Grants to ADIENNE Pharma & Biotech the exclusive Marketing Authorization for the Orphan Drug TEPADINA Commercialization in close cooperation with RIEMSER Arzneimittel AG GreifswaldInsel Riems / Bergamo, March 18, 2010 / b3c...
|
|
|
Comparative in vitro Antimicrobial Activity of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges [Article]
Comparative in vitro Antimicrobial Activity of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges Steven D.Brown* and Maria M...
|
|
|
Roche uniquely positioned to deliver long-term growth
QX: RHHBY) is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.At its first investor conference following the successful integration of...
|
|
|
CNS Response Announces Thompson Board Resignation
- CNS Response, Inc.(OTCBB: CNSO) has announced that Governor Tommy Thompson has resigned from its Board of Directors, and has agreed to become Chairman of its Advisory Board. Thompson said that the resignation was for personal reasons, adding, 'I...
|
|
|
Azur Pharma announces agreement for Prialt
Azur Pharma this week announced the signing of an agreement to acquire Prialt, an analgesic therapy, from Elan.Prialt is indicated in the United States for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who...
|
|
|
Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Pen
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Courtney V.Fletcher, Pharm. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198...
|
|
|
Adienne Pharma Receives EMA Grant For Tepadina Marketing Authorisation
Adienne Pharma & Biotech (Adienne Pharma) and Riemser Arzneimittel have reported that the European Medicines Agency (EMA) has granted exclusive marketing authorisation to Adienne Pharma's orphan medicinal product Tepadina for conditioning treatment prior to...
|
|
|
Do astrocytes really exocytose neurotransmitters?
Nature Reviews Neuroscience 11, 227 (2010).doi:10.1038/nrn2803 Authors: Nicola B. Hamilton & David Attwell In the past 20 years, an extra layer of information processing, in addition to that provided by neurons, has been proposed for the CNS.
|
|
|
Practical considerations on the use of rituximab in autoimmune neurological disorders
Kosmidis ML et al.The authors review the evidencebased effectiveness of rituximab in neurological disorders based on controlled trials and anecdotal reports, including their own experience, and address the immunobiology of Bcells in autoimmune central...
|
|
|
Roche uniquely positioned to deliver long-term growth
Let the jobs come to you!Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system! At its first...
|
|
|
Roche to strengthen global leadership position in oncology, to expand therapeutic areas
Roche is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.At its first investor conference following the successful integration of...
|
|
|
::: European Medicines Agency Grants to ADIENNE Pharma & Biotech the exclusive Marketing Authorization for the
Commercialization in close cooperation with RIEMSER Arzneimittel AGGreifswald-Insel Riems / Bergamo, March 18, 2010 / b3c newswire / - ADIENNE Pharma & Biotech and RIEMSER Arzneimittel AG announce today that the European Medicines Agency (EMA) has granted...
|
|
|
CNS Network Selects ALPHADAS, Logos Technologies Early Phase EDC System
Clinical Trials Update Breaking News News source: Business Wire It is announced today that CNS Network has purchased ALPHADAS, Logos Technologies Incs early phase, e-source data capture system and site automation tools to accelerate and streamline its...
|
|
|
CNS Network Selects ALPHADAS, Logos Technologies Early Phase EDC System
LONDON--(BUSINESS WIRE)--It is announced today that CNS Network has purchased ALPHADAS, Logos Technologies Inc?s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials.ALPHADAS is to be...
|
|
|
Lapatinib plus capecitabine feasible for advanced HER2-positive breast cancer
Br J Cancer 2010; 102: 995-1002 MedWire News: Lapatinib combined with capecitabine is an active treatment option for women with advanced human epidermal growth factor receptor (HER)2-positive breast cancer, including those with progressive central nervous...
|
|
|
Roche aiming to launch 6 new products by end 2014
How to save your taxes and manage your investments Roche, the world's largest maker of cancer drugs, is aiming to build up its strength in the therapeutic areas of metabolism, inflammation and diseases of the central nervous system (CNS) as it tries to...
|
|
|
UPDATE 2-Roche aiming to launch 6 new products by end 2014
* Roche looks to further build up presence outside oncology * May file 35 line extensions of current products by 2014 * Roche stock rises 0.7 percent, in line with index (Adds analyst comment, stock price) ZURICH, March 18 (Reuters) - Roche Holding AG <ROG...
|
|
|
Roche aiming to launch 6 new products by end 2014
ZURICH (Reuters) - Roche Holding AG is aiming to launch at least six new products by the end of 2014 and is seeking to further boost its position in areas outside oncology, the Swiss drugmaker said ahead of its investor day.Roche, the world's largest maker...
|
|
|
UPDATE 2-Roche aiming to launch 6 new products by end 2014
* Roche looks to further build up presence outside oncology * May file 35 line extensions of current products by 2014 * Roche stock rises 0.7 percent, in line with index (Adds analyst comment, stock price) ZURICH, March 18 (Reuters) - Roche Holding AG (ROG.VX...
|
|
|
Roche aiming to launch 6 new products by end 2014
Roche, the world's largest maker of cancer drugs, is aiming to build up its strength in the therapeutic areas of metabolism, inflammation and diseases of the central nervous system (CNS) as it tries to expand its product portfolio.Investors are looking...
|
|
|
Roche aiming to launch 6 new products by end 2014
42 mins ago ZURICH (Reuters) Roche Holding AG is aiming to launch at least six new products by the end of 2014 and is seeking to further boost its position in areas outside oncology, the Swiss drugmaker said ahead of its investor day.Roche, the world's...
|
|
|
UPDATE 2-Roche aiming to launch 6 new products by end 2014
ZURICH, March 18 (Reuters) - Roche Holding AG is aiming to launch at least six new products by the end of 2014 and is seeking to further boost its position in areas outside oncology, the Swiss drugmaker said ahead of its investor day.Roche, the world's...
|
|
|
Roche aiming to launch 6 new products by end of 2014
ZURICH (Reuters) - Roche Holding AG is aiming to launch at least six new products by the end of 2014 and is seeking to further boost its position in areas outside oncology, the Swiss drugmaker said ahead of its investor day.Roche, the world's largest maker...
|
